Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BMRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BMRN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Biomarin Pharmaceutical Inc

BMRN
Current price
59.67 USD +1.32 USD (+2.26%)
Last closed 57.99 USD
ISIN US09061G1013
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 11 027 120 128 USD
Yield for 12 month -27.49 %
1Y
3Y
5Y
10Y
15Y
BMRN
21.11.2021 - 28.11.2021

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California. Address: 770 Lindaro Street, San Rafael, CA, United States, 94901

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

95.80 USD

P/E Ratio

21.30

Dividend Yield

Financials BMRN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BMRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 853 915 000 USD

Last Year

+2 419 226 000 USD

Current Quarter

+745 145 000 USD

Last Quarter

+738 222 000 USD

Current Year

+2 273 680 000 USD

Last Year

+1 842 161 000 USD

Current Quarter

+593 587 000 USD

Last Quarter

+602 083 000 USD
EBITDA 806 617 984 USD
Operating Margin TTM 30.05 %
Price to Earnings 21.30
Return On Assets TTM 6.38 %
PEG Ratio 0.82
Return On Equity TTM 9.64 %
Wall Street Target Price 95.80 USD
Revenue TTM 2 950 226 944 USD
Book Value 30.21 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 14.80 %
Dividend Yield
Gross Profit TTM 2 389 870 080 USD
Earnings per share 2.70 USD
Diluted Eps TTM 2.70 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 108.00 %
Profit Margin 17.76 %

Stock Valuation BMRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 21.30
Forward PE 13.53
Enterprise Value Revenue 3.49
Price Sales TTM 3.74
Enterprise Value EBITDA 13.25
Price Book MRQ 1.89

Technical Indicators BMRN

For 52 Weeks

52.93 USD 94.85 USD
50 Day MA 58.25 USD
Shares Short Prior Month 4 152 237
200 Day MA 64.59 USD
Short Ratio 1.85
Shares Short 4 417 385
Short Percent 2.95 %